Differences

This shows you the differences between two versions of the page.

--- steatohepatitis [2025/09/29 04:59] – [non-alcoholic steatohepatitis (NASH)] gary1
+++ steatohepatitis [2025/11/10 23:00] (current) – [non-alcoholic steatohepatitis (NASH)] gary1
@@ Line 34: / Line 34: @@
     *hypertriglyceridemia
     *chronic PM<sub>2.5</sub> particle exposure (([[https://www.news-medical.net/news/20250205/Study-links-low-levels-of-PM25-exposure-to-liver-damage.aspx]]))
+    *genetic factors(([[https://egastroenterology.bmj.com/content/3/3/e100218|2025: Yang et al: Steatotic liver disease and cancer: from pathogenesis to therapeutic targets]])):
+      * PNPLA3 (I148M, rs738409): the strongest risk allele linked to lipid droplet metabolism dysfunction in hepatocytes and stellate cells, promoting steatosis, fibrosis, and HCC;
+      * TM6SF2 (E167K, rs58542926): impairs very-low-density lipoprotein (VLDL) secretion, leading to triglyceride retention;
+      * MBOAT7 (rs641738): alters phospholipid remodelling and predisposes to hepatic lipid accumulation;
+      * HSD17B13 (rs72613567): confers a protective effect, reducing steatosis and inflammation.
   *it is a progression from nonalcoholic fatty liver disease (NAFLD) which affects ~20% of the population in Western cultures and is rising rapidly due to [[obesity|obesity]]
     *90% of obese patients have NAFLD, while up to 70% of type 2 diabetics have NAFLD